BRPI0511533A - derivados indazol e indolona e seu uso como medicamento - Google Patents

derivados indazol e indolona e seu uso como medicamento

Info

Publication number
BRPI0511533A
BRPI0511533A BRPI0511533-7A BRPI0511533A BRPI0511533A BR PI0511533 A BRPI0511533 A BR PI0511533A BR PI0511533 A BRPI0511533 A BR PI0511533A BR PI0511533 A BRPI0511533 A BR PI0511533A
Authority
BR
Brazil
Prior art keywords
disorders
disorder
sexual
sexual dysfunction
compounds
Prior art date
Application number
BRPI0511533-7A
Other languages
English (en)
Inventor
Charlotte Moira Norfo Allerton
David Hepworth
Duncan Charles Miller
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0411810A external-priority patent/GB0411810D0/en
Priority claimed from GB0415455A external-priority patent/GB0415455D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0511533A publication Critical patent/BRPI0511533A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS INDAZOL E INDOLONA E SEU USO COMO MEDICAMENTO A presente invenção proporciona compostos de fórmula (1), os quais são uma classe de agonistas de dopamina, mais particularmente uma classe de agonistas seletivos para D3 sobre D2. Esses compostos são de utilidade no tratamento e/ou prevenção da disfunção sexual, por exemplo, disfunção sexual feminina (FSD), particularmente, distúrbio de excitação sexual feminino (FSAD), distúrbio do desejo sexual hipoativo (HSDD; falta de interesse por sexo), distúrbio orgástico feminino (FOD, incapacidade de atingir orgasmo), e disfunção sexual masculina, particularmente, disfunção erétil masculina (MED) A disfunção sexual masculina como aqui indicado, significa a inclusão de distúrbios ejaculatórios, tais como ejaculação precoce, anorgasmia (incapacidade de atingir o orgasmo), ou distúrbios do desejo, tais como distúrbio do desejo sexual hipoativo (HSDD), falta de interesse por sexo) Esses compostos são úteis também no tratamento de distúrbios neuropsiquiátricos e distúrbios neurodegenerativos.
BRPI0511533-7A 2004-05-26 2005-05-17 derivados indazol e indolona e seu uso como medicamento BRPI0511533A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411810A GB0411810D0 (en) 2004-05-26 2004-05-26 New indazole and indolone derivatives and their use as pharmaceuticals
GB0415455A GB0415455D0 (en) 2004-07-09 2004-07-09 New indazole and indolone derivatives and their use as pharmaceuticals
PCT/IB2005/001513 WO2005116027A2 (en) 2004-05-26 2005-05-17 Indazole and indolone derivatives and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
BRPI0511533A true BRPI0511533A (pt) 2008-01-02

Family

ID=35219654

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511533-7A BRPI0511533A (pt) 2004-05-26 2005-05-17 derivados indazol e indolona e seu uso como medicamento

Country Status (25)

Country Link
EP (1) EP1753763B1 (pt)
JP (2) JP4093588B2 (pt)
AP (1) AP2006003823A0 (pt)
AR (1) AR049191A1 (pt)
AT (1) ATE404560T1 (pt)
AU (1) AU2005247696A1 (pt)
BR (1) BRPI0511533A (pt)
CA (1) CA2568050A1 (pt)
CR (1) CR8772A (pt)
DE (1) DE602005008954D1 (pt)
EA (1) EA200601985A1 (pt)
EC (1) ECSP067024A (pt)
ES (1) ES2308492T3 (pt)
GT (1) GT200500118A (pt)
IL (1) IL179365A0 (pt)
MA (1) MA28606B1 (pt)
MX (1) MXPA06013759A (pt)
NL (1) NL1029128C2 (pt)
NO (1) NO20065328L (pt)
PA (1) PA8635001A1 (pt)
PE (1) PE20060289A1 (pt)
SV (1) SV2005002128A (pt)
TW (1) TW200607500A (pt)
UY (1) UY28918A1 (pt)
WO (1) WO2005116027A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078411A1 (es) 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
CA2860453C (en) * 2011-01-24 2020-04-28 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
CA2965741C (en) * 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023035A2 (en) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
AU6246198A (en) * 1997-02-18 1998-09-08 American Home Products Corporation 4-aminoethoxyindazole derivatives
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
PT1572214E (pt) * 2002-12-10 2010-05-06 Pfizer Morfolina derivados para utilização como agonistas da dopamina no tratamento da disfunção sexual i.a.

Also Published As

Publication number Publication date
PE20060289A1 (es) 2006-04-22
IL179365A0 (en) 2007-03-08
WO2005116027A3 (en) 2006-04-13
TW200607500A (en) 2006-03-01
ATE404560T1 (de) 2008-08-15
ES2308492T3 (es) 2008-12-01
NL1029128A1 (nl) 2005-11-30
DE602005008954D1 (de) 2008-09-25
EP1753763B1 (en) 2008-08-13
MXPA06013759A (es) 2007-02-08
EP1753763A2 (en) 2007-02-21
JP2008500329A (ja) 2008-01-10
GT200500118A (es) 2006-01-10
AU2005247696A1 (en) 2005-12-08
JP4093588B2 (ja) 2008-06-04
NL1029128C2 (nl) 2006-06-14
ECSP067024A (es) 2006-12-29
EA200601985A1 (ru) 2007-04-27
CA2568050A1 (en) 2005-12-08
MA28606B1 (fr) 2007-05-02
PA8635001A1 (es) 2006-05-16
CR8772A (es) 2006-12-13
WO2005116027A2 (en) 2005-12-08
UY28918A1 (es) 2005-12-30
JP2008074874A (ja) 2008-04-03
SV2005002128A (es) 2005-12-13
NO20065328L (no) 2006-12-18
AR049191A1 (es) 2006-07-05
AP2006003823A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
GEAP202115110A (en) Glp-1 receptor agonists and uses thereof
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
SV2010003714A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CL2013003052A1 (es) Compuestos derivados de 2h-pirazol[3,4-c]-quinolina, 2h-pirazol[3,4-c][1,5 o 1,7]-naftiridina y 2h-benzo[b][1,4]-oxazina, sus composiciones farmaceuticas utiles para el tratamiento de enfermedades y trastornos del aparato respiratorio, anafilaxia sistemica o respuestas de hipersensibilidad entre otras.
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO6602133A2 (es) Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas
ATE412647T1 (de) Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
CL2016000495A1 (es) Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades.
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
CY1118848T1 (el) Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
SV2016005305A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CU24647B1 (es) Moduladores del receptor nmda heteroaromático
EA201070599A1 (ru) Ингибиторы равновесного переносчика нуклеозидов ent1
BRPI0511571A (pt) derivados de aminopiridina como agonistas de dopamina d3 seletivos
AR077958A1 (es) Quinoxalinonas antagonistas de la hepcidina
MX2019009537A (es) Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa).
TW200607500A (en) New indazole and indolone derivatives and their use as pharmaceuticals

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.